Dengue fever affects over 100 million of people globally per year yet there is no developed molecule targeted against Dengue Virus (DENV). Multiple plant-derived compounds, are traditionally used by ethnomedicinal systems, to manage dengue symptoms.  The novel drug molecule designed had a wide therapeutic window (LD 50 = 3500mg/kg) with minimal predicted toxicity, and no blood–brain barrier (BBB) permeability. It had comparable docking score with standard anti-viral and binds at same active site. The molecule so designed can be further analysed for molecular dynamics. Synthesis of this compound can be performed to conduct in-vitro IC 50 studies to demonstrate its anti-viral activities.